Ac lehd cmk

LCL161 was synthesized and provided by Novartis (Basel, Switzerland) under a Material Transfer Agreement (MTA). Obatoclax was purchased from Selleckchem (Houston, TX, USA). Pancaspase inhibitor (Q-VD-OPH), caspase 9 inhibitor (Ac-LEHD-CMK) and caspase 8 inhibitor (Z-IETD-FMK) were purchased from EMD Millipore (Billerica, MA, USA). Akti and chloroquine were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Human DLBCL cell lines were maintained in RPMI-1640 (Lonza; DHL-4, DHL-6, TOLEDO, U2932, K422, RIVA, PFEIFFER) or Iscove’s Modified Dulbecco’s Medium (Lonza; Ly-1, Ly-3, Ly-4, Ly-7, Ly-18, Ly-19, HBL-1), each supplemented with 100 U/mL penicillin, 100 U/mL streptomycin (Lonza), 10% or 20% heat-inactivated fetal bovine serum (Biowest), L-glutamine (2mM, Lonza) and HEPES (10Mm, Lonza). Cell GCB- and ABC designations were determined previously (18 (link)). Cells were grown in a humidified atmosphere at 37°C with 5% CO2. AD-O51.4 was synthesized and provided by Adamed S.A. TRAIL was purchased from R&D. Dynasore, venetoclax, SAHA and panobinostat were purchased from Selleckchem. Methyl-β-cyclodextrin (MβCD) and filipin were purchased from Sigma Aldrich. Caspase 3 inhibitor (Z-DEVD-FMK), caspase 8 inhibitor (Z-IETD-FMK), caspase 9 inhibitor (Ac-LEHD-CMK) and pan-caspase inhibitor (Z-VAD-FMK) were purchased from Merck-Millipore and used at 20 μM (caspase 8 and 9 inhibitors and pan-caspase inhibitor) or 50 μM (caspase 3 inhibitor) final concentration.